Key result
Early initiation of tailored quadruple therapy with ARNi/ACEi, beta-blockers, MRAs, and SGLT2is is recommended as first-line treatment for heart failure with reduced ejection fraction.
This review discusses the historical evolution and current sequencing of pharmacological treatments for heart failure with reduced ejection fraction.
Supports early quadruple therapy in HFrEF; leaves open optimal sequencing from review-level evidence.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Fabiana G. Marcondes‐Braga (2022) conducted an editorial in Heart failure with reduced ejection fraction (HFrEF). Quadruple therapy (ARNi/ACEi, beta-blocker, MRA, SGLT2i) was evaluated. Early initiation of tailored quadruple therapy with ARNi/ACEi, beta-blockers, MRAs, and SGLT2is is recommended as first-line treatment for heart failure with reduced ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: